<DOC>
	<DOC>NCT01074294</DOC>
	<brief_summary>This study tests the effects of an investigational antipsychotic drug (called OPC-34712) in adults with Attention Deficit Hyperactivity Disorder (ADHD) when taken with an approved stimulant medication to explore a possible impact on sleep, quality of life and cognitive function.</brief_summary>
	<brief_title>Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder</brief_title>
	<detailed_description>Subjects who have been taking prescription medication for ADHD, may be switched to a different one. In addition, subjects will be randomly (by chance) assigned to the investigational medication or placebo (pill without active medication). Total study participation lasts 6-20 weeks (up to 5 months). 675 men and women will be in the study at 40 study centers throughout the U.S.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Central Nervous System Stimulants</mesh_term>
	<criteria>Male and female outpatients 18 to 55 years of age, inclusive, at the time of informed consent. Subjects with a primary DSMIVTR diagnosis of ADHD (including inattentive, hyperactive, and combined subtypes) as confirmed by the CAADID. Subjects may have received prior treatment for adult ADHD, may be currently receiving treatment for adult ADHD at screening, or may be treatmentnaive. Subjects willing to discontinue all prohibited psychotropic medication starting from the time of signing the informed consent and during the study period. Females who are breastfeeding and/or who have a positive pregnancy test result prior to receiving study drug. Subjects with an adequate response, as determined by the investigator, to any stimulant taken for the treatment of adult ADHD after 18 years of age. Subjects with a clinically significant current Axis II (DSMIVTR) diagnosis of borderline,antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder. Subjects who participated in a clinical trial within the last 180 days or who participated in more than two clinical trials within the past year.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Inattention</keyword>
	<keyword>Hyperactivity</keyword>
	<keyword>Impulsivity</keyword>
	<keyword>Distractibility</keyword>
	<keyword>Procrastination</keyword>
	<keyword>Disorganized</keyword>
	<keyword>ADHD</keyword>
</DOC>